Induction of Mammary and Other Subcutaneous Neoplasms in Rats by 1-(4-Dimethylaminobenzal)-indene

Abstract

1-(4-DIMETHYLAMINOBENZAL)-INDENE (DABI, Fig. 1) was examined for tumour inhibitory activity against subcutaneous transplants of the Walker carcinosarcoma 256 at the request of Professor C. T. Bahner (Carson–Newman College, Jefferson City, Tennessee). The method used for this test has been described elsewhere¹. A single intraperitoneal or oral administration of DABI in doses of up to 1,600 mg/kg did not kill 6 week old rats, although there was marked loss of body weight in the rats that received doses of more than 400 mg/kg. One intraperitoneal injection of DABI within the range 100–1,600 mg/kg completely inhibited the growth of tumour tissue implanted 24 h previously, and one injection of 50 mg/kg inhibited tumour growth by 75 per cent in comparison with untreated control rats. A single intraperitoneal injection of 1,600 mg/kg, given 8 days after tumour transplantation, slowed tumour growth and caused partial tumour regression in three out of six rats. A single oral dose of DABI in the range 50–1,600 mg/kg had no effect on tumour growth.